VERU
Veru Inc

19,165
Mkt Cap
$55.7M
Volume
0.00
52W High
$14.20
52W Low
$2.64
PE Ratio
-1.95
VERU Fundamentals
50D MA
$3.71
Beta
0.61
Avg. Volume
143,886.62
EPS (Annual)
-$2.80
P/B
3.63
Rev/Employee
$80,411.52
Loading...
Loading...
Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology, and ARDS. The company’s drug development program includes two late-stage novel small molecules, enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator (SARM), is being developed for two indications: (i) Phase 2b clinical study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness and (ii) subject to the availability of sufficient funding, Phase 3 clinical trial of enobosarm for the treatment of androgen receptor positive (AR+), estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The company was founded by William R. Gargiulo, Jr., O. B. Parrish, and Harry Fisch in 1971 and is headquartered in Miami, FL.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
210

Frequently Asked Questions

What is Market Cap of Veru Inc?
What is the 52-week high for Veru Inc?
What is the 52-week low for Veru Inc?
What is the PE ratio of Veru Inc?
What is the Price-to-Book ratio of Veru Inc?
What is the 50-day moving average of Veru Inc?
How many employess does Veru Inc has?

Latest VERU News

View

Advertisement|Remove ads.

Advertisement|Remove ads.